Description

Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C57H97F3N14O15—Research Square Print. 2022 Aug.|Brain Res. 2023 Oct 5:1821:148619.|Oral Dis. 2023 Oct 9.-[1]Boengler K, et al. Connexin 43 impacts on mitochondrial potassium uptake. Front Pharmacol. 2013 Jun 6;4:73.|[2]Wang N, et al. Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res Cardiol. 2013 Jan;108(1):309.—-1275.46–99.93–NCCCC[C@H](N)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@H](C(O)=O)CCCCN)=O)CC1=CC=CC=C1)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O–Cardiovascular Disease–DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)–Gap Junction Protein—-Cytoskeleton–Peptides